Isoniazid (INH)
Sponsors
International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC), Walter K. Kraft
Conditions
Drug Interaction PotentiationHIV Infected Population With Latent TuberculosisHIV InfectionHIV InfectionsHealthy VolunteersHuman Immunodeficiency VirusLTBILatent Tuberculosis
Phase 1
Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women
CompletedNCT02651259
Start: 2017-03-13End: 2019-04-10Updated: 2021-11-04
Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers
CompletedNCT02771249
Start: 2016-06-03End: 2021-08-17Updated: 2022-04-18
Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)
CompletedNCT03510468
Start: 2018-06-12End: 2022-12-21Updated: 2024-08-13
Doravirine, Rifapentine and Isoniazid Interaction
CompletedNCT03886701
Start: 2019-04-22End: 2019-05-20Updated: 2020-03-27
Phase 2
Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV
TerminatedNCT00080119
Start: 2004-02-29End: 2009-05-31Updated: 2019-02-05
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals
TerminatedNCT04272242
Start: 2021-02-27End: 2021-12-27Updated: 2024-09-19
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
RecruitingNCT05383742
Start: 2023-12-07End: 2029-09-15Target: 330Updated: 2025-12-02
Phase 3
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
CompletedNCT01404312
Start: 2012-05-23End: 2017-11-14Updated: 2021-11-04
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
Active, not recruitingNCT03568383
Start: 2019-06-03End: 2027-01-11Updated: 2025-06-15